Tumour-induced angiogenesis: a novel target for drug therapy?

Bibliography

• FOLKMAN J: Fighting cancer by attacking its blood supply. Sci. Am. (1996) 275:150–154.
   PubMed Web of Science ®Google Scholar
• An excellent article written in layman's terms.
   Google Scholar
• FOLKMAN J: Tumor angiogenesis: therapeutic implications. New Engl. J. Med. (1971) 285:1182– 1186.
   PubMed Web of Science ®Google Scholar
• First article proposing that tumour growth is angiogenesis-dependent and that inhibition of angiogenesis could be therapeutic.
   Google Scholar
• FOLKMAN J: The role of angiogenesis in tumor growth. Semin. Cancer Biol. (1992) 3:65–71.
   PubMedGoogle Scholar
• BLOOD CH, ZETTER BR: Tumor interactions with the vasculature: angiogenesis and tumor metastasis. Biochim. Biophys. Acta (1990) 1032:89-118. An excellent review article.
   PubMedGoogle Scholar
• LIOTTA LA, STEEG PS, STETLER-STEVENSON GS: Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell (1991) 64:327–336.
   PubMed Web of Science ®Google Scholar
• FOLKMAN J, SHING Y: Angiogenesis. 1 Biol. Chem. (1992) 267:10931–10934.
   Google Scholar
• A comprehensive review of the field of angiogenesis.
   Google Scholar
• AUERBACH W, AUERBACH R: Angiogenesis inhibition: a review. Pharmac. Ther. (1994) 63:265-311. An excellent review article.
   PubMedGoogle Scholar
• HAYES DF: Angiogenesis and breast cancer. Hematology/Oncology Clinics ofNorth America (1994) 8:51–71.
   PubMed Web of Science ®Google Scholar
• GRAHAM CH, RIVERS J, KERBEL RS, STANKIEWICZ KS, WHITE WL: Extent of vasculariza-tion as a prognostic indicator in thin malignant melanomas. Am. 1 Pathol. (1994) 145:510–514.
   PubMed Web of Science ®Google Scholar
• YAMAZAKI K, ABE S, TAKEKAWA H, et al.: Tumor angiogenesis in human lung adenocarci-noma. Cancer (1994) 74:2245–2250.
   PubMed Web of Science ®Google Scholar
• Mendelsohn J, Howley PM, Israel MA, Liotta LA (Eds.), W.B. Saunders Publishing Co. (1995).
   Google Scholar
• A thorough and up-to date compendium of this field.
   Google Scholar
• DeVita VT, Jr., Hellman S, Rosenberg S (Eds.), J.B. Lippincott Co., Philadelphia, PA (1993).
   Google Scholar
• WINGO PA, TONG T, BOLDEN S: Cancer statistics. CA: A Cancer Journal for Clinicians (1995) 45(1):8–30.
   PubMed Web of Science ®Google Scholar
• HELLMAN S, VOKES EE: Advancing current treatments for cancer. Sci. Am. (1996) 275:118–123.
   PubMed Web of Science ®Google Scholar
• Cancer: Principles and Practice of Oncology. DeVita VT, Jr., Hellman S, Rosenberg SA (Eds.), J.B. Lippincott Co., Philadelphia, PA (1993).
   Google Scholar
• Biologic Therapy of Cancer (Second Edition). DeVita VT, Jr., Hellman S, Rosenberg SA (Eds.), J.B. Lippincott Co., Philadelphia, PA (1995).
   Google Scholar
• KARTNER N, LING V: Multidrug resistance in cancer. Sci. Am. (1989) 260:44–51.
   PubMed Web of Science ®Google Scholar
• WEINSTAT-SASLOW D, STEEG P: Angiogenesis and colonizing in the tumor metastatic process: basic and applied advances. FASEB 1 (1994) 8:401–407.
   Google Scholar
• EZEKOWITZ RAB, MULLIKEN JB, FOLKMANJ: Interferon alpha-2a therapy for life threaten-ing hemangiomas of infancy. New Engl. 1 Med. (1992) 326:1456–1463.
   Google Scholar
• An excellent report describing the usefulness of interferon treatment for haemangiomas.
   Google Scholar
• RICKETTS RR, HATLEY RM, GORDON BJ, SABIO H, HOWELL CG: Interferon-alpha-2a for the treatment of complex hemangiomas of infancy and childhood. Ann. Surg. (1994) 219:605–610.
   Web of Science ®Google Scholar
• LEEK RD, HARRIS AL, LEWIS CE: Cytokine networks in solid human tumors: regulation of angiogenesis. I Leukoc. Biol. (1994) 56:423–432.
   Web of Science ®Google Scholar
• KLAGSBURN M, SASSE J, SULLIVAN R, SMITH JA: Human tumor cells synthesize an endo-thelial cell growth factor that is structurally related to basic fibroblast growth factor. Proc. Natl. Acad. Sci. USA (1986) 83:2448–2452.
   PubMed Web of Science ®Google Scholar
• FERRARA N: Vascular endothelial growth factor. Trends Cardiovasc. Med. (1993) 3:244–250.
   PubMedGoogle Scholar
• A thorough review article.
   Google Scholar
• HORI A, SASADA R, MATSUTANI E, et al.: Suppression of solid tumor growth by immunoneu- tralizing monoclonal antibody against human basic fibroblast growth factor. Cancer Res. (1991) 51:6180–6184.
   PubMed Web of Science ®Google Scholar
• An important study describing the effect of antibodies against bFGF on inhibiting tumour growth.
   Google Scholar
• KIM KJ, LI B, WINER J, et al.: Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo. Nature (1993) 362:841-844.
   Google Scholar
• An important study documenting the role of VEGF.
   Google Scholar
• O'REILLY MS, HOLNGREN L, SHING Y, et al.: Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastasis by a Lewis lung carcinoma. Cell (1994) 79:315-328.
   PubMedGoogle Scholar
• An excellent report describing the characterisation of Angiostatin.
   Google Scholar
• RASTINEJAD F, POLVERINI PJ, BOUCK NP: Regulation of the activity of a new inhibitor of angiogenesis by a cancer suppressor gene. Cell (1989) 56:345-355.
   PubMedGoogle Scholar
• A very important study describing the characterisation of a new inhibitor of angiogenesis.
   Google Scholar
• VAN MEIR EG, POLVERINI PJ, CHAZIN VR, et al.: Release of an inhibitor of angiogenesis upon induction of wild type p53 expression in glioblastoma cells. Nature Genetics (1994) 8:171–176.
   PubMed Web of Science ®Google Scholar
• O'REILLY MS, HOLMGREN L, CHEN C, FOLKMAN J: Angiostatin induces and sustains dormancy of human primary tumors in mice. Nature Medicine (1996) 2:689-692.A very important study documenting the usefulness of angiostatin.
   PubMedGoogle Scholar
• HYNES RO: Integrins: versatility, modulation and signaling in cell adhesion. Cell (1992) 69:11–25.
   PubMed Web of Science ®Google Scholar
• A thorough review article.
   Google Scholar
• RUOSLAHTI E: How cancer spreads. Sci. Am. (1996) 275:72–77.
   PubMedGoogle Scholar
• GUADAGNO TM, OHTSUBO M, ROBERTS JM, ASSOIAN RK: A link between cyclin A expression and adhesion-dependent cell cycle proliferation. Science (1993) 262:1592–1575.
   Web of Science ®Google Scholar
• RUOSLAHTI E, REED JC: Anchorage dependence, integrins and apoptosis. Cell (1994) 77:477–478.
   PubMed Web of Science ®Google Scholar
• BROOKS PC, CLARK RAF, CHERESH DA: Requirement of vascular integrin avf33 for angio- genesis. Science (1994) 264:569–571.
   PubMed Web of Science ®Google Scholar
• An important study describing the requirement of avI33 for angiogenesis.
   Google Scholar
• BROOKS PC, MONTGOMERY AMP, ROSENFELD M, et al.: Integrin av133 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell (1994) 749:1157-1164.An important study documenting the usefulness of antagonists of integrin avI33.
   PubMedGoogle Scholar
• FRIEDLANDER M, BROOKS PC, SHAFFER RW, et al.: Definition of two angiogenic pathways by distinct av integrins. Science (1995) 270:1500–1503.
   Web of Science ®Google Scholar
• RUOSLAHTI E, PIERSHBACHER MD: Arg-Gly-Asp: a versatile cell recognition signal. Cell (1986) 44:517–518.
   PubMed Web of Science ®Google Scholar
• BREM H, GOTO F, BUDSON A, SAUNDERS L, FOLKMAN J: Minimal drug resistance after prolonged anti-angiogenic therapy with AGM-1470. Surgical Forum (1994) XLV:674–677.
   Google Scholar
• KERBEL RS: Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anticancer therapeutic agents. Bio Essays (1991) 13(1 ) :31–36.
   PubMed Web of Science ®Google Scholar
• TEICHER BA, HOLDEN SA, ARA G, SOTOMAYOR EA, DONG HZ: Potentiation of cytotoxic cancer therapies by TNP-470 alone and with other anti-angiogenic agents. Int. J. Cancer (1994) 57:1–6.
   Web of Science ®Google Scholar
• D'AMATO RJ, LOUGHNAN MS, FLYNN E, FOLKMAN J: Thalidomide is an inhibitor of angiogenesis. Proc. Natl. Acad. Sci. USA (1994) 91:4082–4085.
   PubMed Web of Science ®Google Scholar
• INGBER D, FUJITA T, KISHIMOTA S, et al.: Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumor growth. Nature (1990) 348:555–557.
   PubMedGoogle Scholar
• MAIONE TE, GRAY GS, PETRO J, et al.: Inhibition of angiogenesis by recombinant human platelet factor 4 and related peptides. Science (1990) 247:77–79.
   PubMedGoogle Scholar
• CASTELLANI P, VIALE G, DORCARATTO A, et al.: The fibronectin isoform containing the ED-B oncofetal domain: a marker for angiogenesis. Int. J. Cancer (1994) 59:612–618.
   PubMed Web of Science ®Google Scholar
• MOUSA S: Implications of angiogenesis in cancer therapy. Drug and Marketing Development (1995) 6:218–221.
   Google Scholar
• SINGER JW, BURSTEN SL, RICE GC, GORDON WP, BIANCO JA: Inhibitors of intracellular phosphatidic acid production: novel therapeutics with broad clinical applications. Exp. Opin. Invest. Drugs (1994) 3:631–644.
   Google Scholar
• HORWITZ AH, LITTLE R, FADEM M, NADELL R: Peptides from bactericidal/permeability-in-creasing protein (BPI) are cytotoxic for mycoplasma and L-forms of Gram-positive bacteria. ICAAC (1995). Abstract F126.
   Google Scholar
• SAKANIOTO T, ISHIBASHI T, KIMURA H, et al.: Effect of tecogalan sodium on angiogenesis in vitro by choroidal endothelial cells. Invest. Ophthalmol. Vis. Sci. (1995) 36:1076–1083.
   PubMed Web of Science ®Google Scholar
• WATSON SA, MORRIS TM, ROBINSON G, et al.: Inhibition of organ invasion by the matrix metalloproteinase inhibitor batimastat (BB-94) in two human colon carcinoma metastasis mod-els. Cancer Res. (1995) 55:3629–3633.
   PubMed Web of Science ®Google Scholar
• DEVORE R, HELLERQVIST G, WAKEFIELD G, et al.: Phase I study of the antineovascularization drug CM-101. Proc. Am. Soc. Clin. Oncol. (1996) 15:1558A.
   Google Scholar
• KOHN ED, REED E, SAROSY G, et al.: Clinical investigation of a cytostatic calcium influx inhibitor in patients with refractory cancers. Cancer Res. (1996) 56:569–573.
   PubMed Web of Science ®Google Scholar
• LORUSWSO P, WOZNIAK A, PARCHMENT R, et al.: Phase I trial of extended daily dosing of acetyldinaline (CI-994). NCI EORTC Symp. New Drugs Cancer Ther. (1996). Abstract 343.
   Google Scholar
• PLOWMAN GD, ULLRICH A, SHAWVER LK: Receptor tyrosine kinases as targets for drug intervention. Drug News and Perspectives (1994) 7:334–339.
   Google Scholar